The study revealed that Luteolin demonstrated its anticancer effects on HT-29 and SNU-407 colon cancer cell lines by promoting apoptosis, increasing the Nrf2 transcription that is influenced by the enhancement in the DNA methylation of Nrf2 promoter, and by causing an increment in the interaction between Nrf2 and p53. The gene discussed is TP53; the disease is malignant colon neoplasm.